Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML.

J Immunother Cancer · 2024 · PMC11002379 · PMID 38580329

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Moreover, eTCR −/− WT1-TCR T cells showed a trend of increased migration potential toward the target cells and stroma ( figure 5C ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.